Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BCC Research | PRODUCT CODE: 1842137

Cover Image

PUBLISHER: BCC Research | PRODUCT CODE: 1842137

Brain Tumor Therapeutics: Global Markets to 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 2950
PDF & Excel (2-5 Users)
USD 3540
PDF & Excel (Site License)
USD 4248
PDF & Excel (Enterprise License)
USD 5100

Add to Cart

The report provides an analysis of brain tumor therapeutics and analyzes market trends. Using 2024 as the base year, the report provides estimated market data for 2025 through 2030. The market in this report is segmented by therapy type, patient age, end user, and region. The report covers regulatory scenarios, drivers, restraints, opportunities, and the market share for key companies.

Report Scope

This report provides detailed information on brain tumor therapeutics. It analyzes the market trends for brain tumor therapeutics with data from 2024, estimates from 2025, projections of compound annual growth rates through 2030 (forecast period 2025-2030) and regional markets for brain tumor therapeutics. This report highlights brain tumor therapeutics' current and future market potential and providess a detailed competitive environment analysis. The report covers regulatory scenarios, drivers, restraints and opportunities. It also covers market projections for 2030 and the market share for key companies.

This brain tumor therapeutics market is segmented by therapy type into chemotherapy, targeted therapy and immunotherapy. The patient age segment is segmented into adults and pediatrics. The end user segment is segmented into hospitals and home care settings.

The market has been segmented into the following major regions: North America, Europe, Asia-Pacific, the Middle East and Africa and South America. The regional segment covers a detailed analysis of major countries such as the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. For market estimates, 2024 is used as the base year, with forecasts for 2025 and a forecast value for 2030.

The report aims to:

  • Analyze types of brain tumors and related therapeutics.
  • Analyze global market size and segmentation.
  • Understand market constraints and drivers.
  • Provide detailed market forecasts for 2030.
  • Assess market shares, competitiveness and industry structure.
  • Identify potential long-term impacts on the brain tumor therapeutics market.

Report Includes

  • An overview of the current and future global market potential for brain tumor therapeutics
  • Analyses of the global market trends, with historical market revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
  • Estimates of the market size and revenue growth prospects, along with a corresponding market share analysis by therapy type, patient age group, end user and region
  • Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
  • Impact analysis of U.S. tariff laws, as well as use cases of AI adoption on the market
  • Insights derived from Porter's Five Forces model, as well as global supply chain and PESTLE analyses
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
  • A relevant patent analysis, featuring key granted and published patents
  • Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
  • Profiles of the leading companies
Product Code: PHM208B

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Dynamics and Growth Factors
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion

Chapter 2 Market Overview

  • Overview
  • Macroeconomic Factors Analysis
  • Impact of U.S. Tariffs on the Pharmaceutical Industry
  • Healthcare Expenditure
  • Impact of Global Economic Growth on the Pharma Sector
  • Porter's Five Forces Analysis
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Potential for New Entrants
  • Threat of Substitutes
  • Competitiveness in the Industry

Chapter 3 Market Dynamics

  • Market Dynamics
  • Market Drivers
  • Increasing Incidence of Brain Tumor Cases
  • Increasing R&D Spending by Market Players
  • Rise in Government Funding and Pharmaceutical R&D Spending
  • Market Restraints
  • Inadequate Treatment Options for Brain Tumors
  • High Cost of Brain Cancer Drugs
  • Low Screening of Brain Tumors
  • Market Opportunities
  • Increasing Availability of Biosimilars and Generics
  • Research Collaborations

Chapter 4 Regulatory Landscape

  • Regulatory Dynamics
  • U.S.
  • Europe
  • Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

  • Emerging Trends/Technologies
  • Artificial Intelligence
  • Biomarkers
  • Pipeline Analysis
  • Key Takeaways
  • Patent Analysis
  • Key Takeaways

Chapter 6 Market Segment Analysis

  • Segmentation Breakdown
  • Global Brain Tumor Therapeutics Market, by Therapy Type
  • Key Takeaways
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Global Brain Tumor Therapeutics Market, by Patient Age
  • Key Takeaways
  • Adults
  • Pediatric
  • Global Brain Tumor Therapeutics Market, by End User
  • Key Takeaways
  • Hospitals
  • Home Care
  • Geographic Breakdown
  • Global Brain Tumor Therapeutics Market, by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Chapter 7 Competitive Intelligence

  • Key Takeaways
  • Competitive Landscape
  • Company Share Analysis

Chapter 8 Sustainability in Brain Tumor Therapeutics: ESG Perspective

  • Introduction to ESG
  • Sustainability in the Brain Tumor Therapeutics Market
  • ESG Perspective
  • Environmental Impact
  • Social Impact
  • Governance Impact
  • ESG Risk Ratings
  • Conclusion

Chapter 9 Appendix

  • Methodology
  • Abbreviations
  • Sources
  • Company Profiles
  • AMGEN INC.
  • AMNEAL PHARMACEUTICALS LLC.
  • BAXTER
  • BAYER AG
  • F. HOFFMANN-LA ROCHE LTD.
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER INC.
  • SERVIER LABORATORIES
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • Emerging Players/Market Disruptors
Product Code: PHM208B

List of Tables

  • Summary Table : Global Market for Brain Tumor Therapeutics, by Region, Through 2030
  • Table 1 : Global Health Expenditure, by Selected Country, 2021-2023
  • Table 2 : Available Biosimilars of Avastin (bevacizumab) in the Market
  • Table 3 : List of Selected Clinical Trials Studies on Brain Tumor Therapeutics, 2025
  • Table 4 : List of Selected Patents Related to Brain Tumor Therapeutics, 2024-2025
  • Table 5 : Global Market for Brain Tumor Therapeutics, by Therapy Type, Through 2030
  • Table 6 : Global Market for Chemotherapy in Brain Tumor Therapeutics, by Region, Through 2030
  • Table 7 : Global Market for Targeted Therapy in Brain Tumor Therapeutics, by Region, Through 2030
  • Table 8 : Global Market for Immunotherapy in Brain Tumor Therapeutics, by Region, Through 2030
  • Table 9 : Global Market for Brain Tumor Therapeutics, by Patient Age, Through 2030
  • Table 10 : Global Market for Adult Brain Tumor Therapeutics, by Region, Through 2030
  • Table 11 : Global Market for Pediatric Brain Tumor Therapeutics, by Region, Through 2030
  • Table 12 : Global Market for Brain Tumor Therapeutics, by End User, Through 2030
  • Table 13 : Global Market for Brain Tumor Therapeutics for Hospitals, by Region, Through 2030
  • Table 14 : Global Market for Brain Tumor Therapeutics for Home Care Settings, by Region, Through 2030
  • Table 15 : Global Market for Brain Tumor Therapeutics, by Region, Through 2030
  • Table 16 : North American Market for Brain Tumor Therapeutics, by Therapy Type, Through 2030
  • Table 17 : North American Market for Brain Tumor Therapeutics, by Patient Age, Through 2030
  • Table 18 : North American Market for Brain Tumor Therapeutics, by End User, Through 2030
  • Table 19 : North American Market for Brain Tumor Therapeutics, by Country, Through 2030
  • Table 20 : European Market for Brain Tumor Therapeutics, by Therapy Type, Through 2030
  • Table 21 : European Brain Tumor Therapeutics Market, by Patient Age, Through 2030
  • Table 22 : European Market for Brain Tumor Therapeutics, by End User, Through 2030
  • Table 23 : European Market for Brain Tumor Therapeutics, by Country, Through 2030
  • Table 24 : Asia-Pacific Market for Brain Tumor Therapeutics, by Therapy Type, Through 2030
  • Table 25 : Asia-Pacific Market for Brain Tumor Therapeutics, by Patient Age, Through 2030
  • Table 26 : Asia-Pacific Market for Brain Tumor Therapeutics, by End User, Through 2030
  • Table 27 : Asia-Pacific Market for Brain Tumor Therapeutics, by Country, Through 2030
  • Table 28 : South American Market for Brain Tumor Therapeutics, by Therapy Type, Through 2030
  • Table 29 : South American Market for Brain Tumor Therapeutics, by Patient Age, Through 2030
  • Table 30 : South American Market for Brain Tumor Therapeutics, by End User, Through 2030
  • Table 31 : South American Market for Brain Tumor Therapeutics, by Country, Through 2030
  • Table 32 : MEA Market for Brain Tumor Therapeutics, by Therapy Type, Through 2030
  • Table 33 : MEA Market for Brain Tumor Therapeutics, by Patient Age, Through 2030
  • Table 34 : MEA Market for Brain Tumor Therapeutics, by End User, Through 2030
  • Table 35 : MEA Market for Brain Tumor Therapeutics, by Sub-region, Through 2030
  • Table 36 : Key Focus Areas in ESG Metrics
  • Table 37 : ESG Rankings for Leading Companies in Brain Tumor Therapeutics Market, 2025*
  • Table 38 : Abbreviations Used in this Report
  • Table 39 : Information Sources for this Report
  • Table 40 : Amgen Inc.: Company Snapshot
  • Table 41 : Amgen Inc.: Financial Performance, FY 2023 and 2024
  • Table 42 : Amgen Inc.: Product Portfolio
  • Table 43 : Amgen Inc.: News/Key Developments, 2022 and 2023
  • Table 44 : Amneal Pharmaceuticals LLC.: Company Snapshot
  • Table 45 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2023 and 2024
  • Table 46 : Amneal Pharmaceuticals LLC.: Product Portfolio
  • Table 47 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2022
  • Table 48 : Baxter: Company Snapshot
  • Table 49 : Baxter: Financial Performance, FY 2023 and 2024
  • Table 50 : Baxter: Product Portfolio
  • Table 51 : Baxter: News/Key Developments, 2024
  • Table 52 : Bayer AG: Company Snapshot
  • Table 53 : Bayer AG: Financial Performance, FY 2023 and 2024
  • Table 54 : Bayer AG: Product Portfolio
  • Table 55 : Bayer AG: News/Key Developments, 2025
  • Table 56 : F. Hoffmann-La Roche Ltd.: Company Snapshot
  • Table 57 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
  • Table 58 : F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Table 59 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
  • Table 60 : Merck & Co. Inc.: Company Snapshot
  • Table 61 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
  • Table 62 : Merck & Co. Inc.: Product Portfolio
  • Table 63 : Merck & Co. Inc.: News/Key Developments, 2024
  • Table 64 : Novartis AG: Company Snapshot
  • Table 65 : Novartis AG: Financial Performance, FY 2023 and 2024
  • Table 66 : Novartis AG: Product Portfolio
  • Table 67 : Novartis AG: News/Key Developments, 2023
  • Table 68 : Pfizer Inc.: Company Snapshot
  • Table 69 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
  • Table 70 : Pfizer Inc.: Product Portfolio
  • Table 71 : Servier Laboratories: Company Snapshot
  • Table 72 : Servier Laboratories: Financial Performance, FY 2023 and 2024
  • Table 73 : Servier Laboratories: Product Portfolio
  • Table 74 : Servier Laboratories: News/Key Developments, 2023 and 2024
  • Table 75 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
  • Table 76 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
  • Table 77 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
  • Table 78 : Few Emerging Players in the Brain Tumor Therapeutics Market

List of Figures

  • Summary Figure : Global Market Shares of Brain Tumor Therapeutics, by Region, 2024
  • Figure 1 : Porter's Five Forces Analysis of the Brain Tumor Therapeutics Market
  • Figure 2 : Market Dynamics of Brain Tumor Therapeutics
  • Figure 3 : Leading Pharmaceutical Companies' R&D Expenditure, by Function, 2022
  • Figure 4 : U.S. National Cancer Institute Research Funding, 2012-2019
  • Figure 5 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
  • Figure 6 : Global Market Shares of Brain Tumor Therapeutics, by Therapy Type, 2024
  • Figure 7 : Global Market Shares of Chemotherapy in Brain Tumor Therapeutics, by Region, 2024
  • Figure 8 : Global Market Shares of Targeted Therapy in Brain Tumor Therapeutics, by Region, 2024
  • Figure 9 : Global Market Shares of Immunotherapy in Brain Tumor Therapeutics, by Region, 2024
  • Figure 10 : Global Market Shares of Brain Tumor Therapeutics, by Patient Age, 2024
  • Figure 11 : Global Market Shares of Adult Brain Tumor Therapeutics, by Region, 2024
  • Figure 12 : Global Market Shares of Pediatric Brain Tumor Therapeutics, by Region, 2024
  • Figure 13 : Global Market Shares of Brain Tumor Therapeutics, by End User, 2024
  • Figure 14 : Global Market Shares of Brain Tumor Therapeutics for Hospitals, by Region, 2024
  • Figure 15 : Global Market Shares of Brain Tumor Therapeutics for Home Care Settings, by Region, 2024
  • Figure 16 : Global Market Shares of Brain Tumor Therapeutics, by Region, 2024
  • Figure 17 : North American Market Shares of Brain Tumor Therapeutics, by Therapy Type, 2024
  • Figure 18 : North American Market Shares of Brain Tumor Therapeutics, by Patient Age, 2024
  • Figure 19 : North American Market Shares of Brain Tumor Therapeutics, by End User, 2024
  • Figure 20 : North American Market Shares of Brain Tumor Therapeutics, by Country, 2024
  • Figure 21 : European Market Shares of Brain Tumor Therapeutics, by Therapy Type, 2024
  • Figure 22 : European Market Shares of Brain Tumor Therapeutics, by Patient Age, 2024
  • Figure 23 : European Market Shares of Brain Tumor Therapeutics, by End User, 2024
  • Figure 24 : European Market Shares of Brain Tumor Therapeutics, by Country, 2024
  • Figure 25 : Asia-Pacific Market Shares of Brain Tumor Therapeutics, by Therapy Type, 2024
  • Figure 26 : Asia-Pacific Market Shares of Brain Tumor Therapeutics, by Patient Age, 2024
  • Figure 27 : Asia-Pacific Market Shares of Brain Tumor Therapeutics, by End User, 2024
  • Figure 28 : Asia-Pacific Market Shares of Brain Tumor Therapeutics, by Country, 2024
  • Figure 29 : South American Market Shares of Brain Tumor Therapeutics, by Therapy Type, 2024
  • Figure 30 : South American Market Shares of Brain Tumor Therapeutics, by Patient Age, 2024
  • Figure 31 : South American Market Shares of Brain Tumor Therapeutics, by End User, 2024
  • Figure 32 : South American Market Shares of Brain Tumor Therapeutics, by Country, 2024
  • Figure 33 : MEA Market Shares of Brain Tumor Therapeutics, by Therapy Type, 2024
  • Figure 34 : MEA Market Shares of Brain Tumor Therapeutics, by Patient Age, 2024
  • Figure 35 : MEA Market Shares of Brain Tumor Therapeutics, by End User, 2024
  • Figure 36 : MEA Market Shares of Brain Tumor Therapeutics, by Sub-region, 2024
  • Figure 37 : Global Market Shares of Brain Tumor Therapeutics, by Company, 2024
  • Figure 38 : Pillars of ESG
  • Figure 39 : Advantages of ESG for Companies
  • Figure 40 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 41 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 42 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2024
  • Figure 43 : Baxter: Revenue Share, by Business Unit, FY 2024
  • Figure 44 : Baxter: Revenue Share, by Country/Region, FY 2024
  • Figure 45 : Bayer AG: Revenue Share, by Business Unit, FY 2024
  • Figure 46 : Bayer AG: Revenue Share, by Country/Region, FY 2024
  • Figure 47 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
  • Figure 48 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
  • Figure 49 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 50 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 51 : Novartis AG: Revenue Share, by Business Unit, FY 2024
  • Figure 52 : Novartis AG: Revenue Share, by Country/Region, FY 2024
  • Figure 53 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
  • Figure 54 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
  • Figure 55 : Servier Laboratories: Revenue Share, by Business Unit, FY 2024
  • Figure 56 : Servier Laboratories: Revenue Share, by Region, FY 2024
  • Figure 57 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2024
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!